NeuroSense Therapeutics Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Ben-Noon Alon, was filed 17 Jun 2026.
NeuroSense Therapeutics Ltd.: what insiders have been doing
NeuroSense Therapeutics Ltd. is a Health Care company. Its directors and officers file their transactions with SEC (Form 4). In the past year (23 October 2025 to 23 October 2026), 4 filings came from 4 insiders.
Not one open-market sale was filed. On the buying side, 1 insider reported 1 purchase totalling €172k. Unlike grants, an open-market purchase is paid for by the insider, at the market price. On the buying side, the filings list 1 chief executive among the declarants. Biggest ticket of the year: €172k, bought by Ben-Noon Alon and made public on 17 June 2026.
The latest purchase dates back some time: it was published 144 days ago, on 17 June 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4.
With 4 filings in twelve months, the company is quieter than the median of 24 filings across the 3,167 companies we follow on the same exchange. Looking back to 2026, when coverage begins, insiders filed 1 purchase and no sales. The 20-F for the year ended 31 December 2025 shows -11.1 m USD of net income.
Elsewhere in the same sector, our signals recently picked up insider purchases at Dynavox Group AB and EssilorLuxottica. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Who traded when
BuySaleSince the insiders bought
- -84.2%Entry US$16.10 · Close 19 Oct 2026 US$2.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate NeuroSense Therapeutics Ltd. Buy (bullish), based on 3 analysts. Average price target: US$78.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
- 250,000 shares@ US$0.80100.0% of flowOrdinary SharesSEC:0001213900-26-069663:0Canonical exit: 14 Sept 2026 (T+90)
- 200,000 shares0Ordinary SharesSEC:0001213900-26-038545:0
- 200,000 shares0Ordinary SharesSEC:0001213900-26-036432:0
- 200,000 shares0Ordinary SharesSEC:0001213900-26-036022:0
4 of 4 declarations
About NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd. is a biopharmaceutical company focused on developing treatments for neurodegenerative diseases. It is listed on the NASDAQ.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
